141 related articles for article (PubMed ID: 34256895)
21. Prior treatment with oxaliplatin-containing regimens and higher total bilirubin levels are risk factors for neutropenia and febrile neutropenia in patients with gastric or esophagogastric junction cancer receiving weekly paclitaxel and ramucirumab therapy: a single center retrospective study.
Nara K; Yamamoto T; Yamashita H; Yagi K; Takada T; Seto Y; Suzuki H
BMC Cancer; 2023 Oct; 23(1):979. PubMed ID: 37833660
[TBL] [Abstract][Full Text] [Related]
22. Multicenter Phase I/II Study of Nivolumab Combined with Paclitaxel Plus Ramucirumab as Second-line Treatment in Patients with Advanced Gastric Cancer.
Nakajima TE; Kadowaki S; Minashi K; Nishina T; Yamanaka T; Hayashi Y; Izawa N; Muro K; Hironaka S; Kajiwara T; Kawakami Y
Clin Cancer Res; 2021 Feb; 27(4):1029-1036. PubMed ID: 33262133
[TBL] [Abstract][Full Text] [Related]
23. Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study.
Parisi A; Cortellini A; Roberto M; Venditti O; Santini D; Dell'Aquila E; Stellato M; Marchetti P; Occhipinti MA; Zoratto F; Mazzuca F; Tinari N; De Tursi M; Iezzi L; Natoli C; Ratti M; Pizzo C; Ghidini M; Porzio G; Ficorella C; Cannita K
J Cancer Res Clin Oncol; 2019 Sep; 145(9):2365-2373. PubMed ID: 31280347
[TBL] [Abstract][Full Text] [Related]
24. Association between neutropenia and response to ramucirumab and paclitaxel in patients with metastatic gastric cancer.
Roviello G; Conca R; D'Angelo A; Multari AG; Paganini G; Chiriacò G; Petrioli R; Corona SP; Rosellini P; Aieta M
Anticancer Drugs; 2020 Jul; 31(6):632-636. PubMed ID: 32011363
[TBL] [Abstract][Full Text] [Related]
25. [Clinical Efficacy and Safety of Nab-Paclitaxel plus Ramucirumab Therapy in Patients with Unresectable Advanced or Recurrent Gastric Cancer].
Murakami K; Takeno A; Masuzawa T; Imada A; Takase K; Toya K; Yukawa Y; Kawai K; Sakamoto T; Katsura Y; Ohmura Y; Kagawa Y; Hata T; Takeda Y; Murata K
Gan To Kagaku Ryoho; 2020 Mar; 47(3):493-495. PubMed ID: 32381926
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane- and trastuzumab-naïve patients with HER2-positive, previously treated, advanced, or recurrent gastric cancer (JFMC45-1102).
Nishikawa K; Takahashi T; Takaishi H; Miki A; Noshiro H; Yoshikawa T; Nishida Y; Iwasa S; Miwa H; Masuishi T; Boku N; Yamada Y; Kodera Y; Yoshida K; Morita S; Sakamoto J; Saji S; Kitagawa Y
Int J Cancer; 2017 Jan; 140(1):188-196. PubMed ID: 27521503
[TBL] [Abstract][Full Text] [Related]
27. Exposure-response relationship of ramucirumab in East Asian patients from RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer.
Kim TY; Yen CJ; Al-Batran SE; Ferry D; Gao L; Hsu Y; Cheng R; Orlando M; Ohtsu A
Gastric Cancer; 2018 Mar; 21(2):276-284. PubMed ID: 28634748
[TBL] [Abstract][Full Text] [Related]
28. [Efficacy and Safety of Paclitaxel plus Ramucirumab Therapy for Unresectable or Recurrent Gastric Cancer].
Tsujio G; Toyokawa T; Fukuoka T; Tamura T; Ohira G; Shibutani M; Yamazoe S; Nagahara H; Kimura K; Amano R; Tanaka H; Muguruma K; Yashiro M; Maeda K; Hirakawa K; Ohira M
Gan To Kagaku Ryoho; 2019 May; 46(5):895-899. PubMed ID: 31189811
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of Ramucirumab Plus Paclitaxel Among Patients With Previously Treated Metastatic Gastric/Lower Esophageal Cancer: A Real-world Study.
Abdel-Rahman O; Mulder K; Easaw J
Am J Clin Oncol; 2021 Apr; 44(4):158-161. PubMed ID: 33625121
[TBL] [Abstract][Full Text] [Related]
30. [Effect of Hypoalbuminemia on Severe Neutropenia Induced by Paclitaxel Monotherapy and Paclitaxel plus Ramucirumab Combination Therapy in Patients with Gastric Cancer].
Nakazawa Y; Kageyama A; Harada D; Kitamura M; Mitsumori N; Kawakubo T
Gan To Kagaku Ryoho; 2019 May; 46(5):901-905. PubMed ID: 31189812
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of Paclitaxel + Ramucirumab Combination Therapy for Advanced Gastric Cancer Progressing After First-line Chemotherapy in Japan.
Saito S; Muneoka Y; Ishikawa T; Akazawa K
Clin Ther; 2017 Dec; 39(12):2380-2388. PubMed ID: 29175097
[TBL] [Abstract][Full Text] [Related]
32. Ramucirumab: A Review in Advanced Gastric Cancer.
Greig SL; Keating GM
BioDrugs; 2015 Oct; 29(5):341-51. PubMed ID: 26341713
[TBL] [Abstract][Full Text] [Related]
33. Ramucirumab Plus Paclitaxel as a Second-line Chemotherapy in Older Adults With Advanced Gastric Cancer (YCOG1601).
Sato S; Kunisaki C; Tamura Y; Yago A; Kasahara K; Sato T; Kondo H; Kosaka T; Akiyama H; Endo I
Anticancer Res; 2023 Dec; 43(12):5663-5670. PubMed ID: 38030195
[TBL] [Abstract][Full Text] [Related]
34. An observational study on nutrition status in gastric cancer patients receiving ramucirumab plus taxane: BALAST study.
Mizukami T; Miyaji T; Narita Y; Matsushima T; Ogura T; Miyagaki H; Kawabata R; Horie Y; Kawaguchi T; Muro K; Hara H; Yamaguchi T; E Nakajima T
Future Oncol; 2021 Jul; 17(19):2431-2438. PubMed ID: 33764163
[TBL] [Abstract][Full Text] [Related]
35. Ramucirumab and Paclitaxel Administered Every 2 Weeks (mRAINBOW Regimen) in Advanced Gastroesophageal Adenocarcinoma.
Rogers JE; Xiao L; Amlashi FG; Elimova E; Blum Murphy MA; Sanders E; Shanbhag N; Thomas I; Ajani JA
Oncology; 2019; 96(5):252-258. PubMed ID: 30893708
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy.
Kang YK; Ryu MH; Park SH; Kim JG; Kim JW; Cho SH; Park YI; Park SR; Rha SY; Kang MJ; Cho JY; Kang SY; Roh SY; Ryoo BY; Nam BH; Jo YW; Yoon KE; Oh SC
Ann Oncol; 2018 May; 29(5):1220-1226. PubMed ID: 29438463
[TBL] [Abstract][Full Text] [Related]
37. Ramucirumab and paclitaxel in patients with gastric cancer and prior trastuzumab: subgroup analysis from RAINBOW study.
De Vita F; Borg C; Farina G; Geva R; Carton I; Cuku H; Wei R; Muro K
Future Oncol; 2019 Aug; 15(23):2723-2731. PubMed ID: 31234645
[No Abstract] [Full Text] [Related]
38. Cost-effectiveness and safety of ramucirumab plus paclitaxel chemotherapy in the treatment of advanced and recurrent gastric cancer.
Kimura M; Usami E; Teramachi H; Yoshimura T
J Oncol Pharm Pract; 2018 Sep; 24(6):403-411. PubMed ID: 28436252
[TBL] [Abstract][Full Text] [Related]
39. [A Case of Advanced Gastric Cancer with Peritoneal Dissemination after Gastrectomy Successfully Treated with Paclitaxel plus Ramucirumab].
Miyamoto K; Tadano Y; Itoh R
Gan To Kagaku Ryoho; 2021 Jan; 48(1):113-114. PubMed ID: 33468738
[TBL] [Abstract][Full Text] [Related]
40. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
Zielinski C; Láng I; Inbar M; Kahán Z; Greil R; Beslija S; Stemmer SM; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Petruzelka L; Eniu A; Nisenbaum B; Dank M; Anghel R; Messinger D; Brodowicz T;
Lancet Oncol; 2016 Sep; 17(9):1230-9. PubMed ID: 27501767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
